Highlights
Through didactic lectures, tandem talks, debates, keynote lectures, and selected abstract presentations, the Scientific Programme examines a range of gastrointestinal malignancies and offers a mix of dynamic education and exchange.
- Cancer of the Pancreas
- Hereditary Predisposition to Pancreatic Cancer & Surveillance of Patients with Hereditary Predisposition
- Diagnosis and Management of Premalignant Pancreatic Lesions - IPMN
- Debate:Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None
- Flash: Laparoscopic vs Robotic Surgery
- Flash: What is Resectable Pancreatic Cancer & Is There A Role for Complex Surgery – Arterial Resection
- Debate: Resectable Pancreatic Cancer: Neoadjuvant Chemotherapy in All Patients?
- Current Standards & New Emerging Options in Metastatic Pancreatic Cancer
- Cancer of the Biliary Tract
- Molecular Unraveling of Biliary Tract Cancer
- Debate: Are We Ready for Targeted Agents in First-Line Treatment of Advanced Biliary Tract Cancer?
- Locally Advanced Bile Duct Cancer: Criteria and Approaches in Borderline Resectable Disease
- ESMO Session: Focus on Young Oncologists (YO) in Collaboration With ESMO Young Oncologist Committee (YOC)
- Meet the Experts
- Esophageal and Gastric Cancers
- Endoscopic Management of Early Esophageal and Gastric Cancer
- Strategy in Oligometastatic Upper GI Cancer
- Are we ready to Integrate Immunotherapy in Adjuvant and/or Neoadjuvant Settings in Upper GI Cancer?
- Keynote Lecture: Molecular Classification of Gastric Cancer
- Flash: Key Facts on PDL Testing
- Flash: Locally Advanced MSI-H Upper GI Cancer: What is the Optimal Approach?
- Checkpoint Inhibition in Squamous Cell Cancer of the Esophagus
- Checkpoint Inhibition in Metastatic Gastric Adenocarcinoma
- New Targets and Agents in Upper GI Cancer
- Hepatocellular Carcinoma
- Pathogenesis and Subtypes of HCC: NASH & Viral Etiology
- Diagnostic and Imaging Challenges in HCC
- Are we ready to Integrate Systemic Treatment in Early Stages of HCC
- How to Integrate and Sequence New Agents in Advanced HCC?
- Cases With Panel Discussion: Management Strategy in HCC: Locoregional Treatment vs Systemic Treatment
- How to Integrate and Sequence New Agents in HCC
- Minisymposium: The Role of Functional Imaging in GI Cancer
- Minisymposium: Special Topics in Young Adults with Cancer
- Molecular Marker Platforms: Focus on Liquid Biopsies
- Emerging Targets in GI Cancer
- Targeting RAS Mutations
- Targeting the HER2 Pathway in GI Cancer
- Targeting Claudin 18.2 in GI Cancer
- Rectal Cancer
- MRI: New Data and Learnings in Rectal Cancer
- Debate: Is TNT standard of Care in Rectal Cancer?
- Flashes
- Surveillance in Non-Operative Management/Watch & Wait Strategy: How to do?
- How to Integrate CPI in MSI-H Rectal Cancer: Double CPI? Duration? Role of RT?
- Is Robotic Surgery Taking off in Rectal Cancer
- The Challenge of Lateral Lymph Nodes
- Cases With Panel Discussion: Oligometastatic Rectal Cancer
- Adjuvant and Neoadjuvant Treatment of Colon Cancer
- Immune Mechanisms and Microbiome in GI Tumors
- Resistance Factors to IOs
- Microbiome and Colorectal Cancer
- Predicting and Managing Rare Toxicities in GI Cancer Patients
- Toxicity Management: Pneumonitis and Interstitial Lung Disease (ILD)
- Toxicity Management: Nausea and Vomiting
- Surgical Advances in GI Oncology
- Colorectal Cancer: Metastatic Disease
- Algorithms in First-Line and Second-Line Metastatic Disease
- Algorithms in First-Line and Second-Line Metastatic Disease
- GI Oncology: The Past, Present, and Future